Asthma, eczema and food allergies continue to increase throughout the world and are recognised as one of the emerging global health issues.
Global trends now identify allergic diseases as having the most important health and economic impact on both the developed and developing world.
Studies have shown that allergic diseases can progress from one form to another – a phenomenon termed the ‘allergic march’, which now affects 15-30% of children in Western countries. Skin allergy or eczema is usually the first sign of allergic disease in young infants and is often associated with an underlying food allergy. These children are then more likely to go on to develop respiratory allergies, such as asthma and hay fever.
Malaghan Institute staff are frequently asked to share the latest research:
We would like to acknowledge the following organisations and individuals for supporting our research programmes: AgResearch Ltd Hamilton, Fonterra Co-operative Group Ltd, Foundation for Research, Science & Technology, Harry & Beverley Romanes, Health Research Council of New Zealand, Marjorie Barclay Trust, Maurice Wilkins Centre, New Zealand Lottery Health Research, Rex & Betty Coker Scholarship, The Royal Society of New Zealand Marsden Fund, Wellington Medical Research Foundation
How the Malaghan Institute is tackling Asthma & Food Allergy
The treatment of immune-mediated diseases of excessive immune activation, such as asthma and allergy, usually involves the use of non-specific immune suppressive agents such as corticosteroids. Although effective at inhibiting the undesired immune response to allergens, these treatments are non-specific in their mechanism of action and can leave patients more susceptible to common infections such as influenza.
Understanding the signals that trigger the initiation of allergic responses is critical for the identification of specific treatments that selectively suppress only the allergic immune response. Surprisingly, little is known about these signals but scientists at the Malaghan Institute hope to change this by using allergic murine models, immunological assays and structure/function analyses to generate much needed information in this poorly understood field.
Three senior researchers and their staff contribute to the Institute's asthma and allergy research; Prof Graham Le Gros' Allergic and Parasitic Diseases programme, Prof Franca Ronchese's Immune Cell Biology Programme, and Dr Elizabeth Forbes-Blom's Gut Immunology team.
Important outcomes of this work will be the development of generally applicable vaccines and therapies for the treatment of individuals with established disease, and the identification of improved immunological markers for monitoring human airway inflammation and allergy, and a deeper understanding of early life and immune development.